Amgen sells Colorado facility to AstraZeneca for $64.5 million
Thousand Oaks biotech giant Amgen continued its Colorado exit plans recently as it sold a Longmont, Colo., facility to London-based pharmaceutical and biotech company AstraZeneca for $64.5 million. Amgen built the 692,000-square-foot facility in the 1990s to make ingredients for its blockbuster anti-anemia drug Epogen. The site used large vats to produce lines of cell Read More →
Read More →Nurses claim labor law violations in suit against Twin Cities Community Hospital
A group of 53 nurses filed claims against Templeton’s Twin Cities Community Hospital for allegedly violating California labor laws, according to a news release from the law firm Baltodano & Baltodano. The claims were filed in private arbitration on Oct. 3 because of the confidentiality provisions in the nurses’ contracts with the hospital, said Lauren Read More →
Read More →Amgen partners with Swedish company to develop drugs
Thousand Oaks-based Amgen will pay a Swedish company up to $410 million to help it develop oncology and neuroscience drugs. The companies announced the partnership Oct. 4 and said Nuevolution will use its Chemetics drug discovery platform to discover drugs for Amgen. Nuevolution may receive licensing payments along with development, commercial and milestone payments. It Read More →
Read More →Amgen leukemia drug cures 39 percent of treated patients, study finds
Amgen’s new leukemia drug cured 39 percent of pediatric patients who received treatment, the Thousand Oaks company said Oct. 3 after publishing results of a new study in the Journal of Clinical Oncology. Blincyto, which treats a rare form of the disease known as precursor B-cell acute lymphoblastic leukemia, sent 27 patients out of 70 Read More →
Read More →FDA gives big win to Amgen in biosimilars race
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →